Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in Advanced Solid Tumors with KRAS G12C Mutation
2024-515258-25-00Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of glecirasib in Nonhematologic neoplasms, sponsored by Jacobio Pharmaceuticals. Primary endpoints: Safety and tolerability (Phase 1), Treatment-emergent clinical changes (Phase 1) and 3 more. Started Jul 2024; status: completed.
02
Drugs
glecirasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-515258-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515258-25-00.